Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation

Area of Science:

• Molecular Biology
• Cancer Research
• Protein Biochemistry

Background:

• Mdm2 is a primary E3 ubiquitin ligase targeting wild-type and mutant p53 for degradation.
• Post-translational modifications, like phosphorylation, extensively modulate wild-type p53 but poorly affect mutant p53.
• The role of phosphorylation in regulating mutant p53 stability and function is under-investigated.

Purpose of the Study:

• To investigate the role of phosphorylation in regulating mutant p53 stability.
• To determine if specific phosphorylation sites, like Ser392, impact mutant p53 stability and degradation.
• To explore potential therapeutic strategies targeting mutant p53 phosphorylation.

Main Methods:

• Site-directed mutagenesis to create p53 mutants (e.g., p53H175A392).
• Assessment of protein half-life and sensitivity to Mdm2-mediated degradation.
• Analysis of Mdm2/p300 binding and polyubiquitin chain formation.

Main Results:

• Phosphorylation at Serine 392 regulates the stability of the misfolded p53H175 mutant.
• Mutation of Ser392 to alanine shortens p53H175 half-life, increasing Mdm2-mediated degradation.
• This effect is specific to misfolded mutants (p53H175) and not conformationally intact mutants (p53W248).
• Reduced stability of p53H175A392 is independent of Mdm2/p300 binding and polyubiquitin chain formation extent.

Conclusions:

• Mutant p53 stability is regulated by phosphorylation at Ser392.
• Inhibiting Ser392 phosphorylation could be a therapeutic strategy for mutant p53H175 tumors.
• Combining Ser392 phosphorylation inhibition with Mdm2-enhancing agents (e.g., nutlin) may offer a novel treatment approach.